A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

Trial Profile

A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Mar 2017 Planned End Date changed from 1 Jun 2020 to 21 Nov 2020.
    • 21 Mar 2017 Planned primary completion date changed from 1 Jun 2019 to 21 Nov 2019.
    • 21 Mar 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top